Banner Company.jpg

The company

4SC AG is a clinical-stage biopharmaceutical company developing small-molecule drugs that target key indications in cancer with high unmet medical needs. 4SC's pipeline is protected by a comprehensive portfolio of patents and currently comprises two drug candidates in clinical development: resminostat and domatinostat.

4SC aims to generate future growth and to enhance its enterprise value by entering into partnerships with pharmaceutical and biotech companies and/or the eventual marketing and sales of approved drugs in select territories by 4SC itself.


4SC is headquartered in Planegg-Martinsried near Munich, Germany. Contact:


Fraunhoferstr. 22
82152 Planegg-Martinsried

Phone: +49 89 700763-0

Fax: +49 89 700763-29

© EORTC CLTF 20-21, October 14-16 2021, Marseille FRANCE